Voyager Therapeutics, Inc. is set to present eight studies at the upcoming ASGCT 28th Annual Meeting, scheduled for mid-May 2025 in New Orleans, focusing on innovative gene therapies for neurological diseases.

Among the highlights will be an oral presentation on VY1706, a tau silencing gene therapy that previously achieved an impressive 73% knockdown of tau mRNA in non-human primates with a single intravenous dose.

The conference will showcase the efficacy of VY1706, including data from cross-species studies that demonstrate broad central nervous system (CNS) tau lowering in various animal models.

Voyager anticipates submitting two Investigational New Drug applications in 2025 and one in 2026, aiming to validate the performance of their capsids in human trials.

Key presentations will include an oral report on VY1706's CNS penetrance and tau lowering, scheduled for May 15, 2025, by Rajeev Sivasankaran, Ph.D.

The conference will also feature discussions on the efficacy of cross-species blood-brain barrier-penetrant AAV gene therapy and a vectorized anti-amyloid antibody aimed at enhancing CNS expression.

Additional presentations will cover an anti-amyloid gene therapy for Alzheimer's disease and enhancements to Voyager's capsids designed to penetrate the blood-brain barrier.

Voyager's TRACER capsid discovery platform has enabled the development of novel AAV capsids that effectively cross the blood-brain barrier and transduce a wide range of CNS regions.

Data from their TRACER capsids indicate a transduction rate of 43%-98% in neurons and 87%-99% in astrocytes across various brain regions following a single intravenous dose in non-human primates.

Voyager's pipeline targets several neurological diseases, including Alzheimer's, ALS, and Parkinson's, with collaborations involving major pharmaceutical partners like Alexion and Novartis.

The company is also enhancing its gene therapy approaches with features aimed at immune evasion to broaden the treatment population.

The meeting will provide insights into reducing immunogenicity and improving the manufacturability of AAV capsids, including strategies to evade neutralizing antibodies.